HOME >> BIOLOGY >> NEWS
Springer editor and author Koki Horikoshi to receive 2006 Japan Academy Prize

Koki Horikoshi (73), professor emeritus at the Tokyo Institute of Technology and Director General of Extremobiosphere Research Center JAMSTEC, has been honored with this year's Japan Academy Prize. The award ceremony was held on July 3, 2006, in the presence of Their Majesties the Emperor and Empress of Japan.

Prof. Horikoshi received the award for his studies on the diversity, physiology, and application of alkaliphilic microorganisms. He was the first person in the world to isolate alkaliphiles (alkaline-loving microorganisms) and opened up a new vista of the microbial world. His creative studies have influenced microbiology throughout the world and established the foundations of a new field of biological research into extremophiles, i.e. microorganisms that prefer extreme conditions. He has also conducted extensive screening for the enzymes produced by alkaliphiles, and made a great impact on industrial applications.

Koki Horikoshi was born in Saitama (Japan) in 1932. He obtained a B.A. and a Ph.D. from the University of Tokyo. He is the author of Alkaliphiles: Genetic Properties and Applications of Enzymes (2006), published by Springer. He founded Springer's international journal Extremophiles and has helped develop the journal as Editor-in-Chief since 1997. He also set up the International Society for Extremophiles in 2002 as founding president and is a lifetime honorary president of the society. He has received many awards for his scientific work, including the Purple Medal (1987), the Gold Medal from the UK's International Biotechnology Society (1991) and the Honda Prize (1992).


'"/>

Contact: Joan Robinson
joan.robinson@springer.com
496-221-487-8130
Springer
20-Jul-2006


Page: 1

Related biology news :

1. Springer launches Theoretical Ecology
2. Springer ecology book wins award for excellence
3. Springer author receives prestigious award in Beijing
4. Springer adds Genomic Medicine to biomedical publishing portfolio
5. Springer launches new journal, Cognitive Neurodynamics
6. Springer to publish new journal Systems and Synthetic Biology
7. Springer expands life science program with In Vitro journals
8. Springer author Alan Hastings wins Robert H. MacArthur Award
9. Springer acquires BioTribune Magazine and Biotribune.com
10. Springer joins Katrina relief effort with eBooks donation worth more than $1 million
11. Press Week for science writers, reporters and editors

Post Your Comments:
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... ANTONIO , Dec. 12, 2014  Janssen Research ... data at the San Antonio Breast Cancer Symposium (SABCS) ... plus best supportive care (BSC) versus BSC when used ... receiving standard chemotherapy. This non-inferiority trial did not meet ... 15 percent or greater increase in the risk of ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
Cached News: